Eunjung Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Eunjung Kong has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Ikchan Jeon
Department of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea
8 shared publications - Dongwoo Yu
Department of Neurosurgery, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea
4 shared publications - Chan-Hee Lee
Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea
2 shared publications - Cheolpyo Hong
Department of Radiological Science, Catholic University of Daegu, Gyeongbuk 38430, Korea
2 shared publications - Dong Gyu Lee
Department of Physical Medicine and Rehabilitation, Yeungnam University College of Medicine, Daegu, Korea
2 shared publications - Ihn Ho Cho
Department of Nuclear Medicine, Yeungnam University College of Medicine, Daegu, Korea
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 23 (4) , 1005-1021
Novel Magnetic Resonance Imaging (MRI) Features Predicting Relapse After Clinical Remission in Pyogenic Spondylodiscitis: A Study Using Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/MRI Data
Objective: This study aimed to identify magnetic resonance (MR) imaging features that can predict relapse after clinical remission in pyogenic spondylodiscitis (PSD) based on simultaneous ¹⁸F-fluorodeoxyglucose positron emission tomography/MR (¹⁸F-FDG PET/MR) imaging data.Methods: This retrospective study included 101 patients (67 men and 34 women) with thoracic, lumbar, and/or sacral PSD who received at least 4 weeks of parenteral antibiotic therapy. All patients underwent ¹⁸F-FDG PET/MR imaging and blood inflammatory markers at the time of clinical remission and antibiotic discontinuation, and were followed for at least 12 months to detect relapse. Clinical variables and ¹⁸F-FDG PET/MR imaging features associated with relapse were analyzed.Results: Relapse occurred in 21 patients (20.8%) and was significantly associated with PSD lesions confined to the thoracic spine (p=0.016), a higher maximum standardized ¹⁸F-fluorodeoxyglucose uptake value (p=0.048), and higher mean signal intensity of edema at the PSD lesion on MR imaging (p=0.005). Regarding Contrast-Edema Mismatch (relative reduction in the edematous area compared with contrast-enhanced area, grades I–III), grade I (50% difference) in patients with relapse (p=0.016). Additionally, the mean signal intensity of the contrast area remained similar across grades (p=0.320), whereas the mean signal intensity of edema decreased progressively with increasing grade (p<0.001).Conclusion: Persistent and extensive edematous change on MR imaging was significantly associated with relapse after clinical remission in PSD, and may serve as a potential imaging marker for monitoring treatment response and predicting relapse.
- 31 October 2026
- Published by The Korean Spinal Neurosurgery Society in Neurospine
- Vol. 23 (4) , 1005-1021
Open AccessNovel Magnetic Resonance Imaging (MRI) Features Predicting Relapse After Clinical Remission in Pyogenic Spondylodiscitis: A Study Using Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/MRI Data
Objective: This study aimed to identify magnetic resonance (MR) imaging features that can predict relapse after clinical remission in pyogenic spondylodiscitis (PSD) based on simultaneous ¹⁸F-fluorodeoxyglucose positron emission tomography/MR (¹⁸F-FDG PET/MR) imaging data.Methods: This retrospective study included 101 patients (67 men and 34 women) with thoracic, lumbar, and/or sacral PSD who received at least 4 weeks of parenteral antibiotic therapy. All patients underwent ¹⁸F-FDG PET/MR imaging and blood inflammatory markers at the time of clinical remission and antibiotic discontinuation, and were followed for at least 12 months to detect relapse. Clinical variables and ¹⁸F-FDG PET/MR imaging features associated with relapse were analyzed.Results: Relapse occurred in 21 patients (20.8%) and was significantly associated with PSD lesions confined to the thoracic spine (p=0.016), a higher maximum standardized ¹⁸F-fluorodeoxyglucose uptake value (p=0.048), and higher mean signal intensity of edema at the PSD lesion on MR imaging (p=0.005). Regarding Contrast-Edema Mismatch (relative reduction in the edematous area compared with contrast-enhanced area, grades I–III), grade I (50% difference) in patients with relapse (p=0.016). Additionally, the mean signal intensity of the contrast area remained similar across grades (p=0.320), whereas the mean signal intensity of edema decreased progressively with increasing grade (p<0.001).Conclusion: Persistent and extensive edematous change on MR imaging was significantly associated with relapse after clinical remission in PSD, and may serve as a potential imaging marker for monitoring treatment response and predicting relapse.
- Open Access
- 14 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 272
Association Between Sclerostin and Sarcopenia-Related Functional Decline in Older Women
Background: Sclerostin, an osteocyte-derived glycoprotein, plays a key role in bone metabolism by inhibiting the Wnt/β-catenin signaling pathway. While it is a recognized therapeutic target in osteoporosis, its relationship with sarcopenia remains unclear. This study aimed to investigate the associations between serum sclerostin levels, sarcopenia, and osteoporosis in older women. Methods: We conducted a cross-sectional study of 79 postmenopausal women aged ≥65 years. Sarcopenia was defined based on grip strength and appendicular skeletal muscle mass (ASM), osteoporosis was diagnosed according to femoral T-scores, and serum sclerostin levels were measured using ELISA. Associations with clinical variables and bone mineral density (BMD) were evaluated using correlation and logistic regression analyses. Results: Sclerostin levels were significantly higher in women with sarcopenia (p = 0.036) and exhibited a negative correlation with grip strength (r = −0.298, p = 0.008) but not with ASM. Positive correlations were found between sclerostin and multiple femoral BMD parameters. In a logistic regression analysis, sclerostin was modestly associated with sarcopenia (p = 0.045); however, no significant association was observed with osteoporosis (p = 0.257). Conclusions: Elevated sclerostin levels are associated with reduced muscle strength and sarcopenia in older women, independent of muscle mass, indicating that sclerostin may reflect a functional decline in musculoskeletal health. Muscle strength should therefore be considered when interpreting sclerostin’s clinical implications in aging populations.
- 14 January 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (2) , 272
Open AccessAssociation Between Sclerostin and Sarcopenia-Related Functional Decline in Older Women
Background: Sclerostin, an osteocyte-derived glycoprotein, plays a key role in bone metabolism by inhibiting the Wnt/β-catenin signaling pathway. While it is a recognized therapeutic target in osteoporosis, its relationship with sarcopenia remains unclear. This study aimed to investigate the associations between serum sclerostin levels, sarcopenia, and osteoporosis in older women. Methods: We conducted a cross-sectional study of 79 postmenopausal women aged ≥65 years. Sarcopenia was defined based on grip strength and appendicular skeletal muscle mass (ASM), osteoporosis was diagnosed according to femoral T-scores, and serum sclerostin levels were measured using ELISA. Associations with clinical variables and bone mineral density (BMD) were evaluated using correlation and logistic regression analyses. Results: Sclerostin levels were significantly higher in women with sarcopenia (p = 0.036) and exhibited a negative correlation with grip strength (r = −0.298, p = 0.008) but not with ASM. Positive correlations were found between sclerostin and multiple femoral BMD parameters. In a logistic regression analysis, sclerostin was modestly associated with sarcopenia (p = 0.045); however, no significant association was observed with osteoporosis (p = 0.257). Conclusions: Elevated sclerostin levels are associated with reduced muscle strength and sarcopenia in older women, independent of muscle mass, indicating that sclerostin may reflect a functional decline in musculoskeletal health. Muscle strength should therefore be considered when interpreting sclerostin’s clinical implications in aging populations.
- 21 March 2023
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 44 (6) , 488-494
Brain FDG PET for visualizing the relation between impaired lung function and cognitive decline in lung cancer: a preliminary study
Objective: Impaired lung function is associated with an increased risk for cognitive decline. F-18 fluorodeoxyglucose (FDG) PET is a well-known neurodegenerative biomarker for dementia. We investigated the association between lung and brain function using FDG PET in patients with lung cancer. Methods: A random sub-sample of 102 patients with lung cancer and without a self-reported history of neuropsychiatric disorders were recruited and underwent both lung function tests and FDG PET scans before treatment. Lung function was analyzed as the percentage predicted value (% pred) of forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1). FDG uptake was measured as standardized uptake values (SUVs) in the frontal, parietal, temporal, and occipital cortices and cognition-related regions. Regional SUV ratios (SUVRs) were calculated by dividing the SUV in each region by the whole-brain SUV and were then evaluated against lung function indices and clinical variables. Results: After excluding five patients with brain metastases, 97 patients were included in the final analysis (mean age, 67.7 ± 10.3 years). Mean FVC and mean FEV1 were 80.0% ± 15.4% and 77.6% ± 17.8%, respectively. Both FVC and FEV1 were positively correlated with SUVRs in all brain regions after adjusting the data for clinical variables. The degree of decrease in SUVRs related to lung function was not significantly different between cognition-related regions and other regions. Conclusion: Impaired lung function was associated with decreased glucose metabolism in all regions of the brain, indicating that cognitive decline related to decreased glucose metabolism may be due to reduced perfusion.
- 21 March 2023
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 44 (6) , 488-494
Brain FDG PET for visualizing the relation between impaired lung function and cognitive decline in lung cancer: a preliminary study
Objective: Impaired lung function is associated with an increased risk for cognitive decline. F-18 fluorodeoxyglucose (FDG) PET is a well-known neurodegenerative biomarker for dementia. We investigated the association between lung and brain function using FDG PET in patients with lung cancer. Methods: A random sub-sample of 102 patients with lung cancer and without a self-reported history of neuropsychiatric disorders were recruited and underwent both lung function tests and FDG PET scans before treatment. Lung function was analyzed as the percentage predicted value (% pred) of forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1). FDG uptake was measured as standardized uptake values (SUVs) in the frontal, parietal, temporal, and occipital cortices and cognition-related regions. Regional SUV ratios (SUVRs) were calculated by dividing the SUV in each region by the whole-brain SUV and were then evaluated against lung function indices and clinical variables. Results: After excluding five patients with brain metastases, 97 patients were included in the final analysis (mean age, 67.7 ± 10.3 years). Mean FVC and mean FEV1 were 80.0% ± 15.4% and 77.6% ± 17.8%, respectively. Both FVC and FEV1 were positively correlated with SUVRs in all brain regions after adjusting the data for clinical variables. The degree of decrease in SUVRs related to lung function was not significantly different between cognition-related regions and other regions. Conclusion: Impaired lung function was associated with decreased glucose metabolism in all regions of the brain, indicating that cognitive decline related to decreased glucose metabolism may be due to reduced perfusion.
- 28 December 2022
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 102 (6) , e89-e90
Three Reasons for Collaboration Between Physical Medicine and Rehabilitation and Nuclear Medicine Physicians
An abstract is unavailable. This article is available as a PDF only.
- 28 December 2022
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 102 (6) , e89-e90
Three Reasons for Collaboration Between Physical Medicine and Rehabilitation and Nuclear Medicine Physicians
An abstract is unavailable. This article is available as a PDF only.
- Open Access
Assessment of Therapeutic Responses Using a Deep Neural Network Based on 18F-FDG PET and Blood Inflammatory Markers in Pyogenic Vertebral Osteomyelitis
Background and Objectives: This study investigated the usefulness of deep neural network (DNN) models based on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and blood inflammatory markers to assess the therapeutic response in pyogenic vertebral osteomyelitis (PVO). Materials and Methods: This was a retrospective study with prospectively collected data. Seventy-four patients diagnosed with PVO underwent clinical assessment for therapeutic responses based on clinical features during antibiotic therapy. The decisions of the clinical assessment were confirmed as ‘Cured’ or ‘Non-cured’. FDG-PETs were conducted concomitantly regardless of the decision at each clinical assessment. We developed DNN models depending on the use of attributes, including C-reactive protein (CRP), erythrocyte sedimentation ratio (ESR), and maximum standardized FDG uptake values of PVO lesions (SUVmax), and we compared their performances to predict PVO remission. Results: The 126 decisions (80 ‘Cured’ and 46 ‘Non-cured’ patients) were randomly assigned with training and test sets (7:3). We trained DNN models using a training set and evaluated their performances for a test set. DNN model 1 had an accuracy of 76.3% and an area under the receiver operating characteristic curve (AUC) of 0.768 [95% confidence interval, 0.625–0.910] using CRP and ESR, and these values were 79% and 0.804 [0.674–0.933] for DNN model 2 using ESR and SUVmax, 86.8% and 0.851 [0.726–0.976] for DNN model 3 using CRP and SUVmax, and 89.5% and 0.902 [0.804–0.999] for DNN model 4 using ESR, CRP, and SUVmax, respectively. Conclusions: The DNN models using SUVmax showed better performances when predicting the remission of PVO compared to CRP and ESR. The best performance was obtained in the DNN model using all attributes, including CRP, ESR, and SUVmax, which may be helpful for predicting the accurate remission of PVO.
Open AccessAssessment of Therapeutic Responses Using a Deep Neural Network Based on 18F-FDG PET and Blood Inflammatory Markers in Pyogenic Vertebral Osteomyelitis
Background and Objectives: This study investigated the usefulness of deep neural network (DNN) models based on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and blood inflammatory markers to assess the therapeutic response in pyogenic vertebral osteomyelitis (PVO). Materials and Methods: This was a retrospective study with prospectively collected data. Seventy-four patients diagnosed with PVO underwent clinical assessment for therapeutic responses based on clinical features during antibiotic therapy. The decisions of the clinical assessment were confirmed as ‘Cured’ or ‘Non-cured’. FDG-PETs were conducted concomitantly regardless of the decision at each clinical assessment. We developed DNN models depending on the use of attributes, including C-reactive protein (CRP), erythrocyte sedimentation ratio (ESR), and maximum standardized FDG uptake values of PVO lesions (SUVmax), and we compared their performances to predict PVO remission. Results: The 126 decisions (80 ‘Cured’ and 46 ‘Non-cured’ patients) were randomly assigned with training and test sets (7:3). We trained DNN models using a training set and evaluated their performances for a test set. DNN model 1 had an accuracy of 76.3% and an area under the receiver operating characteristic curve (AUC) of 0.768 [95% confidence interval, 0.625–0.910] using CRP and ESR, and these values were 79% and 0.804 [0.674–0.933] for DNN model 2 using ESR and SUVmax, 86.8% and 0.851 [0.726–0.976] for DNN model 3 using CRP and SUVmax, and 89.5% and 0.902 [0.804–0.999] for DNN model 4 using ESR, CRP, and SUVmax, respectively. Conclusions: The DNN models using SUVmax showed better performances when predicting the remission of PVO compared to CRP and ESR. The best performance was obtained in the DNN model using all attributes, including CRP, ESR, and SUVmax, which may be helpful for predicting the accurate remission of PVO.
- Open Access
- 16 May 2022
- Published by Korean Society of Echocardiography in Journal of Cardiovascular Imaging
- Vol. 30 (3) , 181-184
Can C-11 Acetate PET Be a Feasible Option for Assessing Non-Culprit Lesion in STEMI Patients?
- 16 May 2022
- Published by Korean Society of Echocardiography in Journal of Cardiovascular Imaging
- Vol. 30 (3) , 181-184
Open AccessCan C-11 Acetate PET Be a Feasible Option for Assessing Non-Culprit Lesion in STEMI Patients?
- 28 February 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (5) , e421-e422
FDG PET/MRI of Acute Myocarditis After mRNA COVID-19 Vaccination
A 22-year-old man visited the emergency department with chest pain. He had received a second dose of the coronavirus disease 2019 (COVID-19) mRNA (Moderna) vaccine 5 days prior. 18F-FDG PET/MR revealed a focal FDG uptake and late gadolinium enhancement on the basal posterolateral wall of the left ventricle. Myocarditis after a COVID-19 vaccination has been reported predominantly after the second dose of mRNA vaccines in young men. This was a case of acute focal myocarditis after a COVID-19 mRNA vaccination, which was well-visualized by FDG PET/MRI.
- 28 February 2022
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 47 (5) , e421-e422
FDG PET/MRI of Acute Myocarditis After mRNA COVID-19 Vaccination
A 22-year-old man visited the emergency department with chest pain. He had received a second dose of the coronavirus disease 2019 (COVID-19) mRNA (Moderna) vaccine 5 days prior. 18F-FDG PET/MR revealed a focal FDG uptake and late gadolinium enhancement on the basal posterolateral wall of the left ventricle. Myocarditis after a COVID-19 vaccination has been reported predominantly after the second dose of mRNA vaccines in young men. This was a case of acute focal myocarditis after a COVID-19 mRNA vaccination, which was well-visualized by FDG PET/MRI.
- Open Access
- 1 January 2022
- Published by Korean Society of Interventional Cardiology in Journal of Cardiovascular Intervention
- Vol. 1
Clinical Implication of Hybrid PET/MRI for Patients With Chronic Total Occlusion and Severe Left Ventricular Dysfunction
- 1 January 2022
- Published by Korean Society of Interventional Cardiology in Journal of Cardiovascular Intervention
- Vol. 1
Open AccessClinical Implication of Hybrid PET/MRI for Patients With Chronic Total Occlusion and Severe Left Ventricular Dysfunction
- 9 August 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (12) , 1369-1374
The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
Objective: Post Z0011 trial, axillary lymph node dissections (ALNDs) can be performed in patients with ≥3 positive axillary lymph nodes (ALNs). We investigated the diagnostic performance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) to predict ≥3 metastasis [high nodal burden (HNB)]. Methods: We retrospectively analyzed preoperative FDG PET/CT from January 2010 to June 2012. Patients had clinical T1-2N0 primary invasive breast cancer and underwent breast-conserving surgery with sentinel lymph node biopsy ± ALND. All suspicious ALNs were counted considering FDG-avidity with morphologic changes. Images were considered positive if the axillary basin took up more FDG than the surrounding tissue. On CT, abnormal ALNs were round/ovoid or had cortical thickening with contrast enhancement. PET/CT results were compared with the histology and follow-up findings. Results: In total, 221 females with 224 axillae were enrolled; 161 had negative, 53 had 1–2 metastasis [low nodal burden (LNB)] and 10 had HNB. The sensitivity, specificity, negative predictive value and positive predictive value of PET/CT for HNB were 70, 100, 98.6 and 100%, respectively. There was a correlation between the number of suspicious ALNs on PET/CT and the metastatic nodes on final histology. There were no significant differences in age, tumor size and FDG-avidity between patients with negative or LNB and HNB. During follow-up, 25 patients had a recurrence. The three false-negative patients did not show recurrence. Conclusion: Preoperative PET/CT predicts HNB with high accuracy and is useful for evaluating clinical T1-2N0 invasive breast cancer.
- 9 August 2021
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 42 (12) , 1369-1374
The new perspective of PET/CT for axillary nodal staging in early breast cancer patients according to ACOSOG Z0011 trial PET/CT axillary staging according to Z0011
Objective: Post Z0011 trial, axillary lymph node dissections (ALNDs) can be performed in patients with ≥3 positive axillary lymph nodes (ALNs). We investigated the diagnostic performance of 18F-fluorodeoxyglucose PET/computed tomography (FDG PET/CT) to predict ≥3 metastasis [high nodal burden (HNB)]. Methods: We retrospectively analyzed preoperative FDG PET/CT from January 2010 to June 2012. Patients had clinical T1-2N0 primary invasive breast cancer and underwent breast-conserving surgery with sentinel lymph node biopsy ± ALND. All suspicious ALNs were counted considering FDG-avidity with morphologic changes. Images were considered positive if the axillary basin took up more FDG than the surrounding tissue. On CT, abnormal ALNs were round/ovoid or had cortical thickening with contrast enhancement. PET/CT results were compared with the histology and follow-up findings. Results: In total, 221 females with 224 axillae were enrolled; 161 had negative, 53 had 1–2 metastasis [low nodal burden (LNB)] and 10 had HNB. The sensitivity, specificity, negative predictive value and positive predictive value of PET/CT for HNB were 70, 100, 98.6 and 100%, respectively. There was a correlation between the number of suspicious ALNs on PET/CT and the metastatic nodes on final histology. There were no significant differences in age, tumor size and FDG-avidity between patients with negative or LNB and HNB. During follow-up, 25 patients had a recurrence. The three false-negative patients did not show recurrence. Conclusion: Preoperative PET/CT predicts HNB with high accuracy and is useful for evaluating clinical T1-2N0 invasive breast cancer.
- Open Access
Validity of Clinical Assessment Using Clinical Symptoms and C-Reactive Protein for Therapeutic Response in Pyogenic Vertebral Osteomyelitis: Analysis Based on 18F-FDG-PET
Backgroundand objectives: The clinical assessment of therapeutic response in pyogenic vertebral osteomyelitis (PVO) has been usually performed based on the changes of clinical symptoms and blood inflammatory markers. Recently, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has emerged as an alternative independent method. We analyzed the validity of the clinical assessment for detecting residual PVO based on 18F-FDG-PET. Materials and Methods: This study was conducted with 53 patients confirmed as lumbar PVO under retrospective design. All patients underwent clinical assessment using clinical symptoms and C-reactive protein (CRP) for therapeutic response after parenteral antibiotic therapy, which led to the decision of placement in the uncontrolled (group UC) or controlled (group C) group. The validity of clinical assessment was analyzed based on the cut-off values of FDG uptake for detecting residual PVO as references, which are already established in the previous literature. Results: The mean duration of parenteral antibiotic therapy and recurrence rate were 42.19 ± 15.84 (21–89) days and 9.4% (5/53), respectively. 18F-FDG-PETs were performed at 80 rounds of clinical assessment on 37.40 ± 13.15 (21–83) days of parenteral antibiotic therapy and divided: 31 into group UC and 49 into group C, according to the decisions of clinical assessment. Based on the cut-off values of FDG uptake, clinical assessment showed 48.4–58.1% of false positive for residual PVO in group UC. However, 18F-FDG-PET showed 8.2% (4/49) of false negative for residual PVO in group C, which led to recurrences. Conclusions: Clinical assessment using clinical symptoms and CRP for evaluating therapeutic response in PVO is still a useful method in terms of similar recurrence rate compared to 18F-FDG-PET. However, the high rate of false positive for residual PVO can prolong the use of unnecessary antibiotics and overall treatment period.
Open AccessValidity of Clinical Assessment Using Clinical Symptoms and C-Reactive Protein for Therapeutic Response in Pyogenic Vertebral Osteomyelitis: Analysis Based on 18F-FDG-PET
Backgroundand objectives: The clinical assessment of therapeutic response in pyogenic vertebral osteomyelitis (PVO) has been usually performed based on the changes of clinical symptoms and blood inflammatory markers. Recently, 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) has emerged as an alternative independent method. We analyzed the validity of the clinical assessment for detecting residual PVO based on 18F-FDG-PET. Materials and Methods: This study was conducted with 53 patients confirmed as lumbar PVO under retrospective design. All patients underwent clinical assessment using clinical symptoms and C-reactive protein (CRP) for therapeutic response after parenteral antibiotic therapy, which led to the decision of placement in the uncontrolled (group UC) or controlled (group C) group. The validity of clinical assessment was analyzed based on the cut-off values of FDG uptake for detecting residual PVO as references, which are already established in the previous literature. Results: The mean duration of parenteral antibiotic therapy and recurrence rate were 42.19 ± 15.84 (21–89) days and 9.4% (5/53), respectively. 18F-FDG-PETs were performed at 80 rounds of clinical assessment on 37.40 ± 13.15 (21–83) days of parenteral antibiotic therapy and divided: 31 into group UC and 49 into group C, according to the decisions of clinical assessment. Based on the cut-off values of FDG uptake, clinical assessment showed 48.4–58.1% of false positive for residual PVO in group UC. However, 18F-FDG-PET showed 8.2% (4/49) of false negative for residual PVO in group C, which led to recurrences. Conclusions: Clinical assessment using clinical symptoms and CRP for evaluating therapeutic response in PVO is still a useful method in terms of similar recurrence rate compared to 18F-FDG-PET. However, the high rate of false positive for residual PVO can prolong the use of unnecessary antibiotics and overall treatment period.